|
|
|
|
| Symbol(s): |
ONXX |
| Date: |
7-Feb-10 |
| Contributor: |
PriceTarget Research, Inc. |
| Title: |
Onyx Pharmaceuticals has a current Overall Rating of D (Negative). |
| Document Size: |
7 pages |
| Price: |
$25 |
| Document Type: |
Adobe Acrobat Reader®
Download free Adobe Acrobat Reader® |
|
| Research Reports Premium Services |
| ·
|
Get the full report for $25. |
| ·
|
You will have access to this report for 24 hours. |
|
|
|
|
|
| Onyx Pharmaceuticals has a current Overall Rating of D (Negative). Appreciation potential (28) is negative; Power Rating (24) is low. Relative to the S&P 500 Composite, Onyx Pharmaceuticals Inc has both Growth and Value characteristics -- its appeal is likely to be to Capital Gain-oriented investors. ONXX is of the highest investment quality. Onyx Pharmaceuticals' current technical position is very strong. Onyx Pharmaceuticals' Power Rating is 24. ONXX's earnings estimates have...
| | |
|
|
